About
Joe shapes the scientific vision and pipeline execution, guiding cross-functional R&D teams from target discovery through translational research to advance novel therapies toward the clinic.
Before joining Calico, Joe served as Chief Scientific Officer and Head of Research and Development at Sonoma Biotherapeutics from 2023 to 2026, where he oversaw the development of engineered regulatory T cell therapies for autoimmune diseases. From 2021 to 2023, Joe directed discovery and translation of therapeutic targets related to human genetic variation as Chief Scientific Officer at 23andMe Therapeutics. At Genentech from 2006 to 2021, Joe led a laboratory that conducted translational research in respiratory diseases, contributing to multiple therapeutic targets and over 75 publications, and directed target discovery for the Immunology and Ophthalmology therapeutic areas as Vice President and Senior Fellow.
Joe earned his Ph.D. from The Rockefeller University, his M.D. from Weill Medical College of Cornell University and completed undergraduate studies in chemistry at Princeton University.